Peter J. Werth has bought CING on 5 days since Mar 2022

Peter J. Werth is a seasoned pharmaceutical industry executive and current Director of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing next-generation products using its Precision Timed Release™ (PTR™) drug delivery platform for conditions like ADHD and anxiety disorders.( He has served in this role since at least 2023, also designated as a 10 percent owner, and has been involved through Werth Family Investment Associates, LLC, where he serves as manager, converting debt into equity and participating in recent private placements, including the purchase of 19,455 shares and 15,564 warrants on February 6, 2026.(

Werth founded Chemwerth, Inc. in 1982, where he serves as Chief Executive Officer and President, focusing on the chemical aspects of the generic drug business, including research & development, sales, and marketing.( His career highlights include prior work in R&D at Upjohn Pharmaceuticals (now Pfizer) from 1965 to 1975 and as Vice President of Sales and Marketing for Ganes Chemicals, a subsidiary of Siegfried Chemicals, before launching Chemwerth.( As of recent filings, Werth directly holds 92 shares of CING and indirectly controls significant additional holdings through his entity.(

Written by Perplexity from public sources.